Results 251 to 260 of about 2,877,792 (409)

Worth the Effort: Lessons for Discovery and Care From an Unusual Case of Gorlin Syndrome

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Gorlin‐Goltz Syndrome (GGS) is a rare autosomal dominant genetic disorder encompassing a diverse range of clinical manifestations, including congenital anomalies and predisposition to cancer. Pathogenic variants in PTCH1 and SUFU account for up to 79% and 6% of cases, respectively. Currently, an estimated 15%–27% of individuals with a clinical
V. Taliercio   +13 more
wiley   +1 more source

Predicting progression of aortic stenosis by measuring serum calcification propensity

open access: yesClinical Cardiology, Volume 45, Issue 12, Page 1297-1302, December 2022., 2022
Abstract Background The aim of this prospective, double‐blinded study in patients with aortic sclerosis was to determine whether a new calcification propensity measure in the serum could predict disease progression. Methods We included 129 consecutive patients with aortic sclerosis as assessed during a routine clinical echocardiographic exam. Clinical,
Reto Kurmann   +4 more
wiley   +1 more source

MPOWER Tobacco Control Policies' Effects on Lip and Oral Cavity Cancer Trends in MERCOSUR Countries. [PDF]

open access: yesInt J Environ Res Public Health
Hagen LM   +4 more
europepmc   +1 more source

Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti‐IL‐5R Therapy and Requiring Class Switching to Anti‐IL‐4/13

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Type 2 inflammation dominates eosinophilic chronic rhinosinusitis (eCRS) and adult onset asthma. IL‐4, ‐5, and ‐13 are prominent disease mediators. Disease control can be achieved with biologic therapies. However, despite some patients entering remission, others experience poor control. Aim We aimed to describe eCRS patients treated
Peta‐Lee Sacks   +8 more
wiley   +1 more source

Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Severe chronic rhinosinusitis (CRS) is a near universal manifestation of cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor (ETI) is an oral, small molecule, highly effective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector–potentiator drug.
Amanda L. Stapleton   +10 more
wiley   +1 more source

Molecular and cellular paradigms of multidrug resistance in cancer

open access: yesCancer Reports, Volume 5, Issue 12, December 2022., 2022
Abstract Background The acquisition of resistance to chemotherapy is a major hurdle in the successful application of cancer therapy. Several anticancer approaches, including chemotherapies, radiotherapy, surgery and targeted therapies are being employed for the treatment of cancer.
Foram U. Vaidya   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy